TCTR20180207001招募中3 期
Comparison of viral control between two tenofovir dose reduction regimens (300 mg every 48 hours vs 300 mg every 72 hours) in chronic hepatitis B patients with moderate renal impairment from tenofovir induced renal dysfunction.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 100 Years（—）
- 性别
- All
入选标准
- •chronic hepatitis B
- •age equal or more than 18 years old
- •received tenofovir at least 6 months before enrollent, current use of tenofovir mono therapy (dose at least 300 mg q 48 hr)
- •eGFR 30-60 mL/min/1.73 m2
- •suppressible HBV viral load
排除标准
- •known or reversible cause of renal impairment
- •Fanconi syndrome
- •HIV coinfection
- •History of poor drug compliance
- •Hepatocellular carcinoma
研究者
相似试验
已完成
2 期
Clinical trial study on the therapeutic effect of Tenofovir besides routine drug regime (standard of care) in patients with Coronavirus disease 2019 (COVID-19)covid-19.Covid-19, confirmed cases, positive test resultU07.1IRCT20200422047168N1Ahvaz University of Medical Sciences60
已完成
3 期
Comparative study between Entecavir and Tenofovir in the treatment of chronic hepatitis B infection in Thai patientsChronic hepatitis B infectionChronic hepatitis B,Tenofovir,Entecavir,Efficacy,SafetyTCTR20180626002Chulabhorn Hospital442
已完成
3 期
Virological response of switching tenofovir disoproxil fumarate(TDF)-based regimen to abacavir(ABC)-based regimen versus lopinavir/ritonavir(LPV/r) plus lamivudine(3TC) in HIV-infected patients with TDF-induced nephrotoxicity at 24 weeks: a prospective, open-label, randomized controlled trialTenofovir disoproxil fumarate (TDF)-induced nephrotoxicity in HIV infected patientsTDF induced nephrotoxicity,switching,virological response,abacavir,lopinavir/ritonavirTCTR20190708002none84
已完成
不适用
Comparisons of efficacy and safety between Tenofovir and Entecavir drugs in chronic hepatitis B patientsInfections and InfestationsHepatitis BISRCTN18291875Kaohsiung Chang Gung Memorial Hospital288
招募中
3 期
Dolutegravir plus tenofovir alafenamide as a double-drug regimen in HIV positive patientsIRCT20191005044984N1Tehran University of Medical Sciences80